Rights and permissions
About this article
Cite this article
Lenograstim + chemo for SCLC: cost effectiveness “finely balanced”. Pharmacoecon. Outcomes News 505, 9 (2006). https://doi.org/10.2165/00151234-200605050-00030
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605050-00030